How Novartis’s Sandoz Business Performed in Q1
Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics—products that are difficult to develop and manufacture. Sandoz revenue grew 4% YoY (year-over-year) to ~$2.5 billion in the first quarter. The chart below shows Sandoz’s revenue since Q1 2017.